GoodRx Holdings, Inc. (NASDAQ:GDRX) Shares Purchased by Raymond James & Associates

Raymond James & Associates grew its stake in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 212.6% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 394,006 shares of the company's stock after acquiring an additional 267,951 shares during the period. Raymond James & Associates owned about 0.11% of GoodRx worth $2,734,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of GDRX. GSA Capital Partners LLP purchased a new stake in GoodRx in the first quarter worth about $1,638,000. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of GoodRx by 61.1% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 181,512 shares of the company's stock worth $1,289,000 after purchasing an additional 68,835 shares during the period. Jupiter Asset Management Ltd. bought a new position in shares of GoodRx during the first quarter valued at approximately $707,000. Liontrust Investment Partners LLP purchased a new position in GoodRx during the second quarter valued at approximately $520,000. Finally, ClariVest Asset Management LLC bought a new position in GoodRx in the first quarter worth approximately $1,091,000. Hedge funds and other institutional investors own 63.77% of the company's stock.

Insider Buying and Selling at GoodRx

In other news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the company's stock in a transaction dated Tuesday, September 3rd. The stock was sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 4.17% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. Raymond James raised GoodRx from an "outperform" rating to a "strong-buy" rating and set a $10.00 target price on the stock in a research report on Friday, August 9th. UBS Group dropped their price objective on GoodRx from $9.00 to $8.50 and set a "neutral" rating on the stock in a research report on Friday, August 9th. Royal Bank of Canada reiterated an "outperform" rating and issued a $10.00 target price on shares of GoodRx in a report on Friday, August 16th. Finally, Citigroup lowered their price target on shares of GoodRx from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $9.36.

GoodRx Stock Performance

Shares of NASDAQ:GDRX traded up $0.07 during trading on Tuesday, hitting $5.94. The stock had a trading volume of 848,335 shares, compared to its average volume of 1,365,349. The stock has a 50-day simple moving average of $7.10 and a two-hundred day simple moving average of $7.55. The stock has a market capitalization of $2.25 billion, a price-to-earnings ratio of -45.69, a price-to-earnings-growth ratio of 3.91 and a beta of 1.39. GoodRx Holdings, Inc. has a 12-month low of $4.14 and a 12-month high of $9.26. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96.

GoodRx (NASDAQ:GDRX - Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The company reported $0.08 EPS for the quarter, missing the consensus estimate of $0.09 by ($0.01). The business had revenue of $200.60 million for the quarter, compared to analyst estimates of $200.47 million. GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The business's revenue was up 5.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.02 earnings per share. On average, equities research analysts expect that GoodRx Holdings, Inc. will post 0.14 earnings per share for the current fiscal year.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.